← All trials
NCT06498635
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2025
- Primary completion
- Jul 15, 2039
- Completion date
- Jul 15, 2039
- First posted
- Jul 12, 2024
- Last posted
- Jul 12, 2024
- Enrollment
- 306
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- SWOG Cancer Research NetworkOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.